Question 1: To what degree has participating changed your perception of the Collaborative Multispecialty Approach (formerly called the “sandwich method”)?

 

Dr. Abraham: “The study supported my perception that this approach was the ideal way to manage this tumor. In addition, participation in the study and in particular reviewing the data has led me to believe that the “CMA” may be useful not only for non-surgical patients, but also for surgical patients as an adjuvant type of treatment.”

 

Dr. Maale:  “It hasn't. We have participated in these before.”

 

Dr. Randall: “This project has enabled further consideration of the role of CSF-1 inhibitors in the multi-disciplinary approach to TGCT.”

 

Question 2: To what degree will participating impact the care pathways of your patients with TGCT (tenosynovial giant cell tumor)?

 

Dr. Abraham: “We have always presented patients in our tumor board in a multidisciplinary forum, but now we have support from this study that this is the optimal way to make decisions regarding patients with this tumor. It also will serve as a model for other institutions who are interested in managing this tumor.”

 

Dr. Maale: “It will lead us to another study group.”

 

Dr. Randall: “​​CSF1 will likely play a larger role in management of patients with TGCT.”

 

Question 3: What barriers exist in your practice today that would prevent you from implementing the Collaborative Multispecialty Approach (CMA)?

 

Dr. Abraham: “The largest barrier is the current indication of the drug. Since it is not currently approved for patients who are surgical candidates, the applicability to surgical patients is limited.”

 

Dr. Maale: “No barriers. We are set up to do multispecialty IRB.”

​

Dr. Randall: “We are integrated here at UCDH. In non-sarcoma centers, disciplinary care is often more siloed. This study will hopefully help to transform that.”